Sermonix Pharmaceuticals Announces Initiation of Phase 3 ELAINE-3 Study of Lasofoxifene Plus Abemaciclib in Pre- and Post-Menopausal Patients with Locally Advanced or Metastatic ER+/HER2- Breast Cancer with an ESR1 Mutation as Detected by Guardant Health’s Guardant360 CDx Liquid Biopsy Prospective screening of subjects for ESR1 mutations will use the Guardant360 CDx blood test for companion diagnostic developmentPhase 3 study is supported by previously presented ELAINE-1 and...

VBI Vaccines Announces Completion of Enrollment in PROTECT Phase 3 Clinical Study for Sci-B-Vac® Hepatitis B Vaccine More than 1,600 subjects enrolled in PROTECT studyTopline data expected mid-2019 CAMBRIDGE, Mass., April 19, 2018 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (NASDAQ:VBIV) (“VBI”) today announced...